Pharmacological actions of cardipro on cardiovascular system

S Chatterjee1, S N Das, S K Agrawala

  • 1R& D Laboratory, Indian Herbs, Saharanpur - 247 001 Uttar Pradesh, India.

Insights

CARDIPRO, a novel formulation, demonstrates significant cardiovascular benefits. It lowers blood pressure, dilates blood vessels, and enhances heart contractility, offering potential for managing cardiovascular diseases.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Biochemistry

Background:

  • Cardiovascular diseases remain a leading cause of mortality worldwide.
  • There is a continuous need for effective therapeutic agents to manage various cardiovascular disturbances.
  • CARDIPRO is a polyhedral anti-oxidant and cardiotonic formulation proposed for cardiovascular health.

Purpose of the Study:

  • To investigate the pharmacological effects of CARDIPRO on cardiovascular responses.
  • To evaluate its potential as a therapeutic agent for cardiovascular diseases.

Main Methods:

  • In vivo studies: assessed hypotensive effects in dogs and rabbits, and adrenaline potentiation.
  • In vitro studies: examined effects on perfused frog blood vessels, isolated amphibian and mammalian hearts, and isolated rat auricles.
  • Electrocardiogram (ECG) and coronary perfusion flow measurements were conducted.

Main Results:

  • CARDIPRO induced hypotension in dogs and rabbits, an effect blocked by atropine.
  • It potentiated and prolonged adrenaline's hypotensive action.
  • Peripheral vasodilation was observed in frog blood vessels.
  • Positive ionotropic and negative chronotropic effects were noted on isolated hearts.
  • Enhanced contractility in rat auricles and increased coronary perfusion flow in rabbit hearts were observed.
  • No significant per se effect on rabbit ECG.

Conclusions:

  • CARDIPRO exhibits significant cardiotonic, peripheral vasodilating, and coronary vasodilating properties.
  • These combined effects suggest CARDIPRO's potential utility in the management of cardiovascular diseases.

Related Concept Videos

Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...